PL371948A1 - Analogi himbacyny jako antagoniści receptora trombinowego - Google Patents

Analogi himbacyny jako antagoniści receptora trombinowego

Info

Publication number
PL371948A1
PL371948A1 PL02371948A PL37194802A PL371948A1 PL 371948 A1 PL371948 A1 PL 371948A1 PL 02371948 A PL02371948 A PL 02371948A PL 37194802 A PL37194802 A PL 37194802A PL 371948 A1 PL371948 A1 PL 371948A1
Authority
PL
Poland
Prior art keywords
himbacine
analogues
receptor antagonists
thrombin receptor
thrombin
Prior art date
Application number
PL02371948A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Mariappan V. Chelliah
Martin C. Clasby
Yan Xia
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of PL371948A1 publication Critical patent/PL371948A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL02371948A 2001-10-18 2002-10-16 Analogi himbacyny jako antagoniści receptora trombinowego PL371948A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33035901P 2001-10-18 2001-10-18

Publications (1)

Publication Number Publication Date
PL371948A1 true PL371948A1 (pl) 2005-07-11

Family

ID=23289411

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371948A PL371948A1 (pl) 2001-10-18 2002-10-16 Analogi himbacyny jako antagoniści receptora trombinowego

Country Status (23)

Country Link
US (2) US7037920B2 (pl)
EP (1) EP1436298B1 (pl)
JP (2) JP4307260B2 (pl)
KR (1) KR100960170B1 (pl)
CN (1) CN100369917C (pl)
AR (1) AR036832A1 (pl)
AT (1) ATE525378T1 (pl)
AU (1) AU2002335031C1 (pl)
BR (1) BR0213967A (pl)
CA (1) CA2463628A1 (pl)
CO (1) CO5570668A2 (pl)
EC (1) ECSP045064A (pl)
HU (1) HUP0500443A3 (pl)
IL (1) IL160918A0 (pl)
MX (1) MXPA04003610A (pl)
MY (1) MY139335A (pl)
NO (1) NO329349B1 (pl)
NZ (1) NZ531869A (pl)
PE (1) PE20030808A1 (pl)
PL (1) PL371948A1 (pl)
RU (1) RU2319704C9 (pl)
WO (1) WO2003033501A1 (pl)
ZA (1) ZA200402849B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
EP1982984B1 (en) 2002-04-16 2013-02-13 Merck Sharp & Dohme Corp. Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
US20070243632A1 (en) * 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
US7790362B2 (en) * 2003-07-08 2010-09-07 Accumetrics, Inc. Controlled platelet activation to monitor therapy of ADP antagonists
WO2005118576A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
CA2576971A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CA2582353A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
KR20070101216A (ko) * 2004-10-08 2007-10-16 쉐링 코포레이션 트롬빈 수용체 길항제
DK1848705T3 (da) * 2005-01-14 2010-06-14 Schering Corp EXO- og diastereoselektive synteser af himbacin-analoger
AR052871A1 (es) * 2005-01-14 2007-04-11 Schering Corp Una sintesis exo-selectiva de analogos de himbacina
SG158885A1 (en) * 2005-01-14 2010-02-26 Schering Corp Synthesis of himbacine analogs
AU2006230292A1 (en) * 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
US7595169B2 (en) * 2005-04-27 2009-09-29 Accumetrics, Inc. Method for determining percent platelet aggregation
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
JP2009521458A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体
WO2007075964A2 (en) * 2005-12-22 2007-07-05 Schering Corporation Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
MX2008012574A (es) * 2006-03-29 2008-10-10 Schering Corp Derivados de himbacina monociclitos y biciclicos utiles como antagonistas del receptor de trombina.
JP2009533450A (ja) * 2006-04-13 2009-09-17 シェーリング コーポレイション 縮合環トロンビンレセプターアンタゴニスト
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009003761A (es) * 2006-10-04 2009-06-30 Schering Corp Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
MX2009003758A (es) * 2006-10-04 2009-04-22 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
EP2120879A2 (en) * 2006-12-22 2009-11-25 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
US20080299587A1 (en) * 2007-05-03 2008-12-04 Dennis Durbin Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists
MY152040A (en) 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
JP5504259B2 (ja) 2008-05-19 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション 第ixa因子阻害剤としての複素環式化合物
SI2438060T1 (sl) 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
EP2440191A2 (en) 2009-06-08 2012-04-18 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015026685A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
CN104610330A (zh) * 2015-02-25 2015-05-13 成都安斯利生物医药有限公司 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法
CA3189771A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
JP2000229961A (ja) 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト[2,3−c]フラン誘導体およびその製造方法
SK285153B6 (sk) * 1997-11-25 2006-07-07 Schering Corporation Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
DE19801636A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
KR100604742B1 (ko) 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제

Also Published As

Publication number Publication date
AU2002335031B2 (en) 2005-06-30
ATE525378T1 (de) 2011-10-15
CN1571789A (zh) 2005-01-26
US20030203927A1 (en) 2003-10-30
AR036832A1 (es) 2004-10-06
KR20050036845A (ko) 2005-04-20
NZ531869A (en) 2006-11-30
ECSP045064A (es) 2004-05-28
JP2009029820A (ja) 2009-02-12
MY139335A (en) 2009-09-30
CN100369917C (zh) 2008-02-20
JP4307260B2 (ja) 2009-08-05
HUP0500443A3 (en) 2009-12-28
MXPA04003610A (es) 2004-07-27
NO329349B1 (no) 2010-10-04
PE20030808A1 (es) 2003-09-22
BR0213967A (pt) 2005-08-30
IL160918A0 (en) 2004-08-31
WO2003033501A1 (en) 2003-04-24
CA2463628A1 (en) 2003-04-24
EP1436298A1 (en) 2004-07-14
KR100960170B1 (ko) 2010-05-26
RU2004115114A (ru) 2005-10-27
US7037920B2 (en) 2006-05-02
US20060106050A1 (en) 2006-05-18
RU2319704C2 (ru) 2008-03-20
NO20042021L (no) 2004-05-14
EP1436298B1 (en) 2011-09-21
AU2002335031C1 (en) 2006-11-16
RU2319704C9 (ru) 2008-08-20
CO5570668A2 (es) 2005-10-31
HUP0500443A2 (hu) 2005-08-29
ZA200402849B (en) 2005-01-14
JP2005529841A (ja) 2005-10-06

Similar Documents

Publication Publication Date Title
IL160918A0 (en) Himbacine analogues as thrombin receptor antagonists
IL153308A0 (en) Thrombin receptor antagonists
IL174538A0 (en) Thrombin receptor antagonists
IL164585A0 (en) Tricyclic thrombin receptor antagonists
EP1553075A4 (en) LPA Receptor Antagonists
IL165841A0 (en) Mchir antagonists
SI1562595T1 (sl) Diaril etri kot antagonisti opiodnega receptorja
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
PL376509A1 (pl) Antagoniści IL-15
EP1351933A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
DK1571145T3 (da) Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister
AU2003251739A8 (en) New neuropeptide y y5 receptor antagonists
GB0130261D0 (en) Lactams as tachykinin antagonists
IL163939A0 (en) Nk1 antagonists
PL370799A1 (pl) Pochodne aminotetraliny jako antagoniści receptorów muskarynowych
PL362838A1 (pl) Antagoniści somatostatyny
IL157713A0 (en) Aryl oxime-piperazines useful as ccr5 antagonists
AU2003297773A8 (en) Heteroaryl peptidomimetics as thrombin receptor antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
GB0101223D0 (en) Histamine receptor antagonists
PL370821A1 (pl) N-Ureidopiperydyny jako antagoniści VIII receptora CCR-3
PL370367A1 (pl) Antagoniści V receptora CCR-3
HK1065797A (en) Himbacine analogues as thrombin receptor antagonists
GB0026327D0 (en) Thrombin receptor antagonists
AU2003223329A8 (en) Antagonists of rf-amide neuropeptides

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)